ApconiX at EUROTOX 2018

Dr Michael Morton, Professor Ruth Roberts, Dr Richard Knight and Dr Paul Duffy will be attending EUROTOX this September in Brussels. The theme for 2018 is “Toxicology Out of the Box” and reflects the federation’s willingness and enthusiasm to offer an innovative, forward-looking and imaginative scientific programme.  ‘"The theme for EUROTOX aligns perfectly with our [...]

By |2018-08-15T09:24:31+00:00August 15th, 2018|Toxicology, Events|Comments Off on ApconiX at EUROTOX 2018

Changes in the metabolome and microRNA levels in biological fluids might represent biomarkers of neurotoxicity: A trimethyltin study.

Abstract: Neurotoxicity has been linked with exposure to a number of common drugs and chemicals, yet efficient, accurate, and minimally invasive methods to detect it are lacking. Fluid-based biomarkers such as those found in serum, plasma, urine, and cerebrospinal fluid have great potential due to the relative ease of sampling but at present, data on [...]

By |2018-06-27T16:11:13+00:00February 28th, 2018|Toxicology, Publications|Comments Off on Changes in the metabolome and microRNA levels in biological fluids might represent biomarkers of neurotoxicity: A trimethyltin study.

Attitude Toward Safety in Needs to Change

A co-founder of the company ApconiX, based in Alderley Park, has revealed his view that attitude towards safety in pre-clinical cancer drug development needs to change. “There is still huge unmet need in effective cancer treatment and it can be tempting for companies researching new drugs to focus mainly on efficacy data with safety issues [...]

By |2018-06-27T16:32:28+00:00February 20th, 2018|Press|Comments Off on Attitude Toward Safety in Needs to Change

Learning from Failure

Cardiovascular toxicity often hinders success – are companies picking the wrong compounds? Prolific novelist and academic CS Lewis once said, “Failures are finger posts on the road to achievement.” (Given pharma’s drug failure rate, the road ahead must truly be paved in gold.) When it comes to drug safety failure, toxicity – especially to the [...]

By |2018-07-11T15:26:46+00:00November 2nd, 2017|Ion Channels, Press|Comments Off on Learning from Failure

New Drug Discovery Alliance to Tackle High Rate of Failure

Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development. This alliance will provide both high-throughput ion channel screening, advanced cardiovascular safety testing models and experienced project scientists in one collaborative team. This enables both large and small pharmaceutical companies to make the right [...]

By |2018-06-27T16:34:31+00:00September 20th, 2017|Press|Comments Off on New Drug Discovery Alliance to Tackle High Rate of Failure

ApconiX New Year Message 2017!

As we get ready for a busy and exciting 2017, it’s a good time to reflect on ApconiX’s first full year in business and share some notable highlights. In 2016 we were joined by several additional preclinical experts including Dr Guy Healing, Dr Damian Deavall, Dr Jane Barber, Dr Mike O’Donovan and Dr Peter Ballard [...]

By |2018-06-06T14:51:39+00:00January 6th, 2017|Press|Comments Off on ApconiX New Year Message 2017!